The invention is directed to compositions comprising a modified dextran and to uses thereof for the treatment of wounds in a subject or for delivering a protein, an olignonucleotide, a pharmaceutical agent, or a mixture thereof to a subject. The modified dextran in the compositions can form hydrogels via crosslinking.

The present invention relates to a medical composition and a method for preparing the same, the medical composition comprising: an adipose tissue-derived extracellular matrix powder; and a biocompatible polymer or a crosslinked product of the biocompatible polymer. The medical composition according to the present invention exists in a well-aggregated state even after implantation in the body and can maintain the volume thereof for a certain time.

The present invention relates to a fibrocartilage preparation method and fibrocartilage prepared by the method.

The present invention relates to a decellularized nerve graft using allogeneic and heterologous nervous tissues and a method of manufacturing the same.

In the present invention, by using a low-concentration basic solution and a surfactant as a decellularization solution, cell and tissue toxicity caused by a solvent or surfactant remaining in the tissue may be minimized by minimizing the use of a basic solution and an anionic surfactant in the entire manufacturing process. In addition, a peristaltic pump may be used to maintain the tissue structure and effectively remove lipid and cells.

Methods of forming a gel and related methods of treating subjects with such gels are described. The method may include preparing a composition by combining a macromer comprising a first polyethylene glycol (PEG)-based polymer, a poly(ethylenimine)-based polymer, or a poly(1,2-glycerol) carbonate-based polymer, the macromer including at least one first functional moiety, a crosslinking agent comprising a second PEG-based polymer that includes at least one second functional moiety, and a photoinitiator, and activating the photoinitiator via a light source to form the gel.

Compositions of matter comprising decellularized omentum are disclosed. The compositions may be scaffolds, hydrogels or hydrogel precursor compositions. Methods of generating the compositions are disclosed as well as uses thereof.

The present invention relates to shaped, bone fiber-based products and methods to make the same.

A method of producing an acellular peripheral nerve graft comprises the steps of providing a section of peripheral nerve, primary treatment of the section of peripheral nerve comprising freezing and then thawing the section of peripheral nerve, freeze-drying the thawed section of peripheral nerve longitudinally to introduce longitudinal pores into the section of peripheral nerve, and decellularization of the section of peripheral nerve comprising contacting the freeze-dried section of peripheral nerve with detergent and enzymatic decellularization agents to provide the acellular peripheral nerve graft. 9. The acellular peripheral nerve graft typically has an average pore size of at least 40 μm and a DNA content of less than 100 ng/mg.

A biocompatible adhesive is provided comprising one or more water insoluble compounds of structure (1) wherein B is an oligomer derived from a polyester, polyether, polyalkylene glycol, polysilicone or polycarbonate with a MW<10,000 g/mol, Linker L is a urethane, urea bond, or amide bond; Linker L′ is a urethane or urea bond, A is a chain extender of Mw≤3000 g/mol comprising substituted or unsubstituted alkyl, cycloalkyl and/or aromatic groups, W is a terminal adhesive benzene-1,2-diol derivative or a terminal adhesive benzene-1,2,3-diol derivative, m is 0 or 1; and n is 0, 1, 2, 3 or 4; or a cross-linked polymer formed from said compounds. The compound(s) have a Tg lower than 25° C. The biocompatible adhesive is suitable for use without solvent.

A fetal-origin decellularized nucleus pulposus (NP) allogenic material to regenerate a host's Intervertebral Disc (IVD). The decellularized NP material, obtained from a vertebrate fetus and characterized by comprising high levels of collagen 12 and 14, is used in a pharmacological composition for the treatment of IVD degeneration. The advance is based on the increased ability of the fetal decellularized NP material to stimulate the host constituent cell's to increase the expression of collagen 2 and aggrecan, promoting intrinsic IVD regeneration. A related method includes preparing the pharmaceutical compositions of fetal decellularized material in the form of fragments/microparticles and hydrogel for an injectable mode of administration. The involved material, pharmaceutical compositions and methods may be advantageously used for the prevention and treatment of IVD degeneration and back pain in human and veterinary settings.